Market Access
From Supplier to Public Health Player: The Changing Role of Biopharma Companies
Cell and gene therapies, collectively termed Advanced Therapy Medicinal Products (ATMPs) in the EU, ...
Physician Opinions About “Fair” Prices Vary for Certain Therapies
As the cost of pharmaceutical and biotechnology therapies continues to rise, concern about the ...
First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization
There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...
The Unintended Consequences Behind Gilead’s Remdesivir Pricing Announcement
At the end of June, Gilead announced its long-awaited pricing strategy for remdesivir, which ...
The Ever-Evolving Remote Patient Monitoring Reimbursement Landscape
The urgency of the COVID-19 pandemic has illustrated how essential telehealth services are to ...
Value-Based Healthcare—Demonstrating Value in an Era of Increased Scrutiny and Accountability
Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...
Small Drug Features May Have Big Value in the COVID World
When I was an access decision maker at a leading pharmacy benefit manager (PBM), ...
Three Changes for Patient Access Programs Following COVID-19’s Increase in Uninsured Patients
The long-term impacts of the COVID-19 pandemic—across the globe and in the U.S.—cannot be ...
Pharma Must Demonstrate Better Outcomes for Pay-Per-Performance
In the dramatically changing pharma industry, one key trend that overlays providers of care, ...
COVID-19: How are Payers Managing These Days?
If there’s one thing we know about payers, it’s they hate surprises. That’s why ...
Is Significant Change on the Horizon for Payers, Pricing, and Pharma?
Thanks to the 2020 presidential election, pharma companies can expect plenty of talk from ...
Two Key Questions About Payer Strategies in 2020
PM360 asked experts within market access strategies whether pricing regulation will impact 2020 and ...
Demonstrating Value in the Real World
New therapies are hitting the market at an unprecedented pace, and the innovation behind ...
